CAR T-Cells Targeting the Integrin αvβ6 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid Malignancies

Engineering for Success: Approaches to Improve Chimeric Antigen Receptor T Cell Therapy for Solid Tumors

(2019) Melinda Mata et al.   DRUGS

Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial

(2018) Gregory L. Beatty et al.   GASTROENTEROLOGY

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

(2018) Jae H. Park et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Integrin αvβ6 Promotes Lung Cancer Proliferation and Metastasis through Upregulation of IL-8–Mediated MAPK/ERK Signaling

(2018) Pengwei Yan et al.   Translational Oncology

Clinically compliant spatial and temporal imaging of chimeric antigen receptor T-cells

(2018) Nia Emami-Shahri et al.   Nature Communications

CSF1R + Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype

(2018) Juliana B. Candido et al.   Cell Reports

Preclinical Development and First-in-Human Imaging of the Integrin αvβ6 with [18F]αvβ6-Binding Peptide in Metastatic Carcinoma

(2018) Sven H. Hausner et al.   CLINICAL CANCER RESEARCH

Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA + Metastatic Colorectal Cancers

(2017) Chengcheng Zhang et al.   MOLECULAR THERAPY

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma

(2017) Andras Heczey et al.   MOLECULAR THERAPY

Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells

(2017) Lynsey M. Whilding et al.   MOLECULAR THERAPY

Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells

(2017) Thomas Shum et al.   Cancer Discovery

Improved migration of tumor ascites lymphocytes to ovarian cancer microenvironment by CXCR2 transduction

(2017) Manja Idorn et al.   OncoImmunology

Integrins as Therapeutic Targets: Successes and Cancers

(2017) Sabine Raab-Westphal et al.   Cancers

The integrin αvβ6: a novel target for CAR T-cell immunotherapy?

(2016) Lynsey M. Whilding et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Pharmacological Characterization of the αvβ6 Integrin Binding and Internalization Kinetics of the Foot-and-Mouth Disease Virus Derived Peptide A20FMDV2

(2016) Robert J. Slack et al.   PHARMACOLOGY

Integrin αvβ6 and matrix metalloproteinase 9 correlate with survival in gastric cancer

(2016) Pei-Long Lian et al.   WORLD JOURNAL OF GASTROENTEROLOGY

CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma

(2016) T. Chao et al.   Cancer Immunology Research

Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma

(2015) Nabil Ahmed et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

(2015) James N. Kochenderfer et al.   JOURNAL OF CLINICAL ONCOLOGY

CAR T-cell immunotherapy: The path from the by-road to the freeway?

(2015) Lynsey M. Whilding et al.   Molecular Oncology

Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes

(2015) Ignazio Caruana et al.   NATURE MEDICINE

Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma

(2015) Laura A. Johnson et al.   Science Translational Medicine

Interleukin-8 promotes cell migration through integrin αvβ6 upregulation in colorectal cancer

(2014) Qi Sun et al.   CANCER LETTERS

Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins

(2014) M. F. Sanmamed et al.   CLINICAL CANCER RESEARCH

Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor

(2014) S. Wilkie et al.   JOURNAL OF IMMUNOLOGY

Therapeutic Targeting of Integrin αvβ6 in Breast Cancer

(2014) Kate M. Moore et al.   JNCI-Journal of the National Cancer Institute

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

(2014) M. L. Davila et al.   Science Translational Medicine

EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss

(2013) J. H. Sampson et al.   CLINICAL CANCER RESEARCH

Preclinical In Vivo Modeling of Cytokine Release Syndrome Induced by ErbB-Retargeted Human T Cells: Identifying a Window of Therapeutic Opportunity?

(2013) S. J. C. van der Stegen et al.   JOURNAL OF IMMUNOLOGY

Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity

(2013) Cor HJ Lamers et al.   MOLECULAR THERAPY

Design of a Phase I Clinical Trial to Evaluate Intratumoral Delivery of ErbB-Targeted Chimeric Antigen Receptor T-Cells in Locally Advanced or Recurrent Head and Neck Cancer

(2013) May C.I. van Schalkwyk et al.   Human Gene Therapy Clinical Development

Integrin-mediated regulation of TGFβ in fibrosis

(2012) Neil C. Henderson et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling

(2012) Scott Wilkie et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Unknown

(2012) David Davies et al.   MOLECULAR MEDICINE

A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis and modulates key biomarkers in vivo

(2012) C Eberlein et al.   ONCOGENE

Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor

(2011) E. K. Moon et al.   CLINICAL CANCER RESEARCH

Transduction of Tumor-Specific T Cells with CXCR2 Chemokine Receptor Improves Migration to Tumor and Antitumor Immune Responses

(2010) W. Peng et al.   CLINICAL CANCER RESEARCH

Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b

(2010) John A. Craddock et al.   JOURNAL OF IMMUNOTHERAPY

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY

T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model

(2009) A. Di Stasi et al.   BLOOD

Immunotherapy for Osteosarcoma: Genetic Modification of T cells Overcomes Low Levels of Tumor Antigen Expression

(2009) Nabil Ahmed et al.   MOLECULAR THERAPY

Antibody-Mediated Blockade of Integrin  v 6 Inhibits Tumor Progression In vivo by a Transforming Growth Factor- Regulated Mechanism

(2008) L. A. Koopman Van Aarsen et al.   CANCER RESEARCH